Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dermira Inc.
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
- Specialty Pharmaceuticals
- Topical Delivery
- Large Molecule
- Other Names / Subsidiaries
- Valocor Therapeutics, Inc.